Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on TherapeuticsMD (TXMD) yesterday and set a price target of $27. The company’s shares closed yesterday at $5.09.
Chen said:
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for TXMD shares. We think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus forecasts will drive TXMD’s stock higher. We like the stock ahead of what we expect to be better-than-expected uptake for in 2019+.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 10.1% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
TherapeuticsMD has an analyst consensus of Moderate Buy, with a price target consensus of $20.50, which is a 302.8% upside from current levels. In a report issued on February 10, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $3.51. Currently, TherapeuticsMD has an average volume of 3.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
